Boehringer Ingelheim has developed a scaffold-manufacturing toolbox based on an E. coli production platform for a variety of affinity scaffold proteins and antibody derivatives, such as single-chain antibodies (scFv), Nanobodies®, Anticalins® and others.
Our long-term expertise in the biopharmaceutical business enables us to provide short development times due to efficient and robust manufacturing processes. Continually optimized high cell-density fermentation processes allow for product titers exceeding 10 g/L. Semi-automated refolding and chromatography resin screening support a fast and effective development of the subsequent downstream process.
The Nanobody® toolbox, for example, consists of a modular vector concept, different expression systems in E. coli and yeast, and an efficient refolding and purification platform.
In addition to process developments and transfers Boehringer Ingelheim BioXcellence™ offers E. coli expression feasibility studies for new antibody derivates and scaffold molecules. Starting from the cDNA of a given molecule, research material appropriate for pre-clinical in vivo studies including a preliminary downstream process can be provided within three to four months.